| Literature DB >> 34204428 |
Satriya Pranata1,2, Shu-Fang Vivienne Wu1, Javad Alizargar3, Ju-Han Liu1, Shu-Yuan Liang1, Yu-Ying Lu1.
Abstract
Diabetes is a prevalent disease with a high risk of complications. The number of people with diabetes worldwide was reported to increase every year. However, new integrated individualized health care related to diabetes is insufficiently developed.Entities:
Keywords: diabetes mellitus; glycemic control; patient care team; personal health services
Year: 2021 PMID: 34204428 PMCID: PMC8296342 DOI: 10.3390/ijerph18126535
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flowchart of screening articles on PHC for diabetes.
Extraction of PHC Elements for Patients With diabetes.
| No | Method | Population | PG/LS | BB/EB | GT | PP | GC | ICP | SM | PRDC | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Abbate, Mannucci, Cioni, Fatini, and Marcucci (2012) [ | LR | Type 1 and type 2 diabetes | × | |||||||
| 2. | Meneghini & Reid (2012) [ | LR | Type 2 diabetes | × | × | × | |||||
| 3. | Spiegel and Hawkins (2012) [ | LR | Type 2 diabetes | × | × | ||||||
| 4. | Paschou and Leslie (2013) [ | LR | Type 2 diabetes | × | × | × | |||||
| 5. | Subramanian and Hirsch (2014) [ | LR | Type 2 diabetes | × | × | × | |||||
| 6. | Davies et al. (2015) [ | RCT | Type 2 diabetes | × | |||||||
| 7. | Groop, (2015) [ | LR | Type 1 and type 2 diabetes | × | |||||||
| 8. | Jameson and Longo (2015) [ | LR | Type 1 and type 2 diabetes | × | × | ||||||
| 9. | Sexton (2016) [ | LR | Interdisciplinary teamwork care | × | |||||||
| 10. | Sherifali et al. (2016) [ | LR | Type 2 diabetes | × | |||||||
| 11. | Sherifali (2016) [ | LR | Type 2 diabetes | × | × | ||||||
| 12. | Krag et al. (2016) [ | RCT | Type 2 diabetes | × | |||||||
| 13. | Miñambres, Mediavilla, Sarroca, and Pérez (2016) [ | CSA | Type 2 diabetes | × | × | ||||||
| 14. | Pearson (2016) [ | LR | Type 2 diabetes | × | × | ||||||
| 15. | Fradkin, Hanlon, and Rodgers (2016) [ | LR | Type 1 and type 2 diabetes | × | × | ||||||
| 16. | Holt (2016) [ | LR | Type 2 diabetes | × | × | × | |||||
| 17. | Florez (2016) [ | LR | Type 1 and type 2 diabetes | × | |||||||
| 18. | Meyer (2016) [ | LR | Type 2 diabetes | × | |||||||
| 19. | Arnett and Claas (2016) [ | LR | Type 1 and type 2 diabetes | × | |||||||
| 20. | Scheen (2016) [ | LR | Type 2 diabetes | × | |||||||
| 21. | Floyd and Psaty (2016) [ | LR | Type 2 diabetes | × | |||||||
| 22. | Rich and Cefalu (2016) [ | LR | Type 2 diabetes | × | × | ||||||
| 23. | Krinsley, Preiser, and Hirsch (2017) [ | CHT | Type 2 diabetes | × | × | ||||||
| 24. | Sherifali (2017) [ | LR | Type 2 diabetes | × | |||||||
| 25. | Mahato, Srivastava, and Chandra (2017) [ | LR | Type 1 and type 2 diabetes | × | |||||||
| 26. | Mayor (2017) [ | LR | Type 2 diabetes | × | × | × | × | × | |||
| 27. | Mutie, Giordano, and Franks (2017) [ | LR | Type 2 diabetes | × | × | ||||||
| 28. | Fitipaldi, McCarthy, Florez, and Franks (2018) [ | LR | Type 2 diabetes | × | × | ||||||
| 29. | Horwitz, Charlson, and Singer (2018) [ | LR | Type 2 diabetes | × | |||||||
| 30. | Greener (2018) [ | LR | Type 1 and type 2 diabetes | × | × | ||||||
| 31. | Burke, Trinidad, and Schenck (2019) [ | LR | Type 2 diabetes | × | |||||||
| 32. | Mannino, Andreozzi, and Sesti (2019) [ | LR | Type 2 diabetes | × | |||||||
| 33. | Mohan and Radha (2019) [ | LR | Type 1 and type 2 diabetes | × | × | ||||||
| 34. | Leggio, Tiberti, Armeni, Limongelli, and Mazza (2019) [ | LR | Type 2 diabetes | × | × | ||||||
| 35. | Prasad and Groop (2019) [ | LR | Type 2 diabetes | × | × |
Note: LR: literature review; CSA: cross-sectional analysis; RCT: randomized controlled trial; CHT: cohort study; PG/LS: personalized genetic or lifestyle; BB/EB: biodata- or evidence-based; GT: glycemic target; PP: patient preferences; GC: glycemic control; ICP: interdisciplinary collaboration practice; SM: self-management; PRDC: Patient priority direct care.
Elements, Concept Descriptions, and Clinical Strategies on PHC for Diabetes.
| No | Elements | Concept Description | Clinical Strategies |
|---|---|---|---|
| 1. | Personalized genetic or lifestyle | - Genetic or lifestyle analysis; genomic test screening for diabetes autoantibodies that remain after a drug or insulin dose, gene encoding glucokinase, presence of | - Assessment of risk of complication by using risk prediction charts, genotype, or electronic health records |
| 2. | Biodata-or evidence-based | - Genetic examination to detect various potential health problems, cardiovascular disease, a person’s metabolic ability to a nutrient, and HbA1c target | - Electronic health records and ADA guidelines |
| 3. | Glycemic target | - Based on ADA guidelines, target and therapy differ based on the features and responses of each individual (including HbA1c, blood pressure, and cholesterol) | - Shared decision-making assessment tool |
| 4. | Patient preferences | - Identification of whether the patient needs additional medication and their concern regarding hyper/hypoglycemia, further expressing their decision | - Shared decision-making assessment tool |
| 5. | Glycemic control | - Supporting the use of a potent drug to achieve a reduction in HbA1c to <6.5%. | - HbA1c based on ADA guidelines |
| 6. | Interdisciplinary collaboration practice | - Teamwork entails discussion of the most appropriate treatment for patients | - Shared decision-making among patients, nurses, physicians, etc. |
| 7. | Self-management | - Individualizing therapy so that patients can effectively self-manage their disease through increasing self-efficacy | - Diabetes SM education, self-efficacy enhancing intervention program |
| 8. | Patient priority direct care | - Assess the individual as a whole including the complex interplay of comorbid conditions, psychosocial, functional status, and individual need | - Shared decision-making assessment tool |
Note: ADA: American Diabetes Association; SM: self-management.
Figure 2Strategies to clinically apply eight PHC elements for treating patients with diabetes.